Navigation Links
Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers' Diarrhea Patch at Keystone Conference
Date:10/11/2007

ttp://www.iomai.com.

Some matters discussed in this press release constitute "forward-looking statements" that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements about the patch vaccine being a prophylaxis for travelers' diarrhea, the timing for commencing Phase 3 studies, the potential size of the market for a travelers' diarrhea vaccine; the applicability of TCI technology to other pathogens; and that, if approved, Iomai's vaccine would be the first available in the U.S. Applicable risks and uncertainties include, among others, that Iomai may not be able to enroll sufficient numbers of patients in future clinical trials; that future clinical trials may not replicate results seen in the trial described in this press release; that Iomai may be unable to obtain the regulatory approvals necessary to conduct additional clinical trials or to market any product for travelers' diarrhea; that estimates of market size overstate the number of travelers who would use such a product, if it were approved; that competitors may develop products that are safer, more effective, or more convenient to use; and the risks identified under the heading "Factors That May Impact Future Results" in Management's Discussion and Analysis of Financial Condition and Results of Operations in Iomai's Quarterly Report on Form 10-Q for the three months ended June 30, 2007, and filed with the Securities and Exchange Commission. While Iomai believes that this product candidate is amenable to self-administration, in the Phase 2 study described in this press release, medical professionals administered the vaccine. Whether any approved product would be self-administered would depend on many factors, including the outcome of any studies the Company conducts evaluating self-administration and the views of regulatory agencies. Iom
'/>"/>

SOURCE Iomai Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. State technology chief endorses IT audit recommendations
2. Fusion 2007: CA chief says IT complexity raises risk
3. Web-Based Learning Developed under new Chief Education Officer
4. UW-Madisons Beebe wins scientific award
5. Researchers say scientific reporting needs more perspective, less hype
6. Wisconsin stands at the center of scientific efforts to avert flu epidemics
7. Growth prompts new location for scientific instrument manufacturer
8. UW stem cell guru outlines scientific and political future
9. Wisconsin biotech sector featured in scientific magazine
10. Scientific Protein Laboratories Acquired by New York firm
11. GenTel Appoints Burke to its Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con ... europeo in occasione di Hi Europe 2014 (dal 2 ... Si tratta della curcumina con la maggiore biodisponibilità ... cristalli) e ingredienti approvati dalle norme europee. ... della pianta curcumina ( Curcuma longa ) che è ...
(Date:11/24/2014)... , Nov. 24, 2014  IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... to the U.S. Food and Drug Administration (FDA), which ... 2014 to seven, with eighteen submissions now pending at ... President and CEO of the Company, commented, "Our team ...
(Date:11/24/2014)... 2014  Last week, Representatives Gus Bilirakis ... took a bold bipartisan step on behalf of ... Act. Original co-sponsors of the legislation include Representatives ... incentivize drug makers and innovators to "repurpose" major ... cancers, which opens the door to the development ...
(Date:11/24/2014)...   First published ... Elsevier , a world-leading provider of scientific, technical ... the launch of the latest title in the Current ... Food Science . Current ... new platform to keep up-to-date with the expanding volume of ...
Breaking Biology Technology:La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... Biosciences, Inc.,(Nasdaq: RDEA ) today announced that preclinical data will ... Digestive Disease Week (DDW) 2008 in San Diego., The ... Date/Time: Tuesday, May 20, 2008 at 3:30 p.m. Pacific Time ... Selective MEK Inhibitor Ameliorates Murine ...
... CHICAGO, May 14 Last month a lawsuit ... of Davenport,Iowa resident, Mark Scott who suffered the tragic ... The complaint was filed On April 1, 2008 in,the ... and alleges that,Melissa Scott,s untimely death was caused by ...
... Augments Senior Management Team with Recent Strategic Hires ... ... May 14 Triple-S,Management Corporation (NYSE: GTS ) today announced that ... for the Children,s Oncology Group and,the Dana Farber Acute Lymphoblastic Leukemia Consortium, ...
Cached Biology Technology:Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008 2Iowa Resident Dies After Using Contaminated Blood Thinner 2Iowa Resident Dies After Using Contaminated Blood Thinner 3Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director 2
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
(Date:11/10/2014)... U.S. store shelves in early 2010, and people have ... packets can be tossed into a washing machine without ... The convenience, though, has come with risks for young ... Children,s Hospital found that from 2012 through 2013, U.S. ... than 6 years of age swallowing, inhaling, or otherwise ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3
... Understanding the structure, function, and development of the ... the great scientific challenges of our time. The ... to create unique databases and analytical tools for ... them to brain research and linking them with ...
... embedded with bright, light-emitting molecules have enabled researchers ... below the skin surface using only infrared light. ... based at the University of Pennsylvania and the ... porphyrins within the surface of a polymersome, a ...
... Although new HIV treatments have drastically reduced the ... remains a health threat in many developing countries. ... sarcoma ?a cancer-like viral disease traditionally associated with ... Howard Hughes Medical Institute (HHMI) investigator, and HHMI ...
Cached Biology News:Wiley announces publication of Databasing the Brain 2Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin 2How an AIDS-Related Cancer Unleashes Inflammation 2How an AIDS-Related Cancer Unleashes Inflammation 3
Request Info...
Purified anti-eIF-4E...
Peptide-affinity Purified Polyclonal Antibody to SMAD7 Peptide with sequence SSCPCWLEVIFNSR, from C Terminus of the protein sequence according to NP_005895....
Purified anti-PXR...
Biology Products: